TY - JOUR
T1 - External beam radiotherapy for unresectable hepatocellular carcinoma, an international multicenter phase I trial, SAKK 77/07 and SASL 26
AU - Herrmann, Evelyn
AU - Naehrig, Diana
AU - Sassowsky, Manfred
AU - Bigler, Martin
AU - Buijsen, Jeroen
AU - Ciernik, Ilja
AU - Zwahlen, Daniel
AU - Pellanda, Alessandra Franzetti
AU - Meister, Andreas
AU - Brauchli, Peter
AU - Berardi, Simona
AU - Kuettel, Erika
AU - Dufour, Jean-Francois
AU - Aebersold, Daniel M.
AU - Swiss Group for Clinical Cancer Research (SAKK)
PY - 2017
Y1 - 2017
N2 - Purpose: To assess feasibility and safety of conventionally fractionated radiotherapy (cfRT) in patients with hepatocellular carcinoma (HCC).Methods: Patients with histologically confirmed stage cT1-4, cN0-1 HCC and Child-Pugh Score (CPS) A or B disease were included in a phase I multicenter trial. Metastatic HCC were allowed if >= 90% of total tumor volume was located within the liver. Patients were enrolled onto five dose-escalation levels (54-70Gy in 2Gy fractions) based on a modified 3 + 3 design, with cohorts of five patients instead of three patients in dose levels 4 and 5. Primary trial endpoint was dose-limiting toxicity (DLT), as specifically defined for 17 clinical and nine laboratory parameters as grade >= 3 or >= 4 toxicity (CTCAE vs. 3). The threshold to declare a dose level as maximum tolerated dose (MTD) was defined as a DLT rate ofResults: The trial was terminated early in DL 3 due to low accrual. Nineteen patients were recruited. Fifteen patients were evaluable for the primary and 18 for the secondary endpoints. Maximum tolerated dose was not reached. One patient in dose level 1, and one patient in dose level 2 experienced DLT (lipase > 5xULN, and neutrophilsConclusion: Conventionally fractionated radiotherapy of 58Gy to even large HCC was safe for patients with CPS A and B. 62Gy was delivered to three patients without any sign of clinically relevant increased toxicity. The maximum tolerated dose could not be determined.
AB - Purpose: To assess feasibility and safety of conventionally fractionated radiotherapy (cfRT) in patients with hepatocellular carcinoma (HCC).Methods: Patients with histologically confirmed stage cT1-4, cN0-1 HCC and Child-Pugh Score (CPS) A or B disease were included in a phase I multicenter trial. Metastatic HCC were allowed if >= 90% of total tumor volume was located within the liver. Patients were enrolled onto five dose-escalation levels (54-70Gy in 2Gy fractions) based on a modified 3 + 3 design, with cohorts of five patients instead of three patients in dose levels 4 and 5. Primary trial endpoint was dose-limiting toxicity (DLT), as specifically defined for 17 clinical and nine laboratory parameters as grade >= 3 or >= 4 toxicity (CTCAE vs. 3). The threshold to declare a dose level as maximum tolerated dose (MTD) was defined as a DLT rate ofResults: The trial was terminated early in DL 3 due to low accrual. Nineteen patients were recruited. Fifteen patients were evaluable for the primary and 18 for the secondary endpoints. Maximum tolerated dose was not reached. One patient in dose level 1, and one patient in dose level 2 experienced DLT (lipase > 5xULN, and neutrophilsConclusion: Conventionally fractionated radiotherapy of 58Gy to even large HCC was safe for patients with CPS A and B. 62Gy was delivered to three patients without any sign of clinically relevant increased toxicity. The maximum tolerated dose could not be determined.
KW - Hepatocellular carcinoma
KW - Conformal radiotherapy
KW - Liver
KW - Radiation toxicity
KW - STEREOTACTIC BODY RADIOTHERAPY
KW - CONFORMAL RADIATION-THERAPY
KW - TRANSCATHETER ARTERIAL CHEMOEMBOLIZATION
KW - INDUCED LIVER-DISEASE
KW - TRANSARTERIAL CHEMOEMBOLIZATION
KW - NORMAL TISSUE
KW - INTRAHEPATIC MALIGNANCIES
KW - RADIOFREQUENCY ABLATION
KW - HEPATOBILIARY CANCERS
KW - MRECIST RESPONSES
U2 - 10.1186/s13014-016-0745-0
DO - 10.1186/s13014-016-0745-0
M3 - Article
C2 - 28086942
SN - 1748-717X
VL - 12
JO - Radiation Oncology
JF - Radiation Oncology
M1 - 12
ER -